Fig 1: EGCG diminishes Tau hyperphosphorylation and BACE1 expression in hippocampus of AD rats. Sham-operated rats were used as controls, whereas AD rats were untreated or treated with 100 mg/kg EGCG, 250 mg/kg EGCG and 625 mg/kg EGCG. (A) Immunohistochemistry determination of Tau phosphorylation in rat hippocampus (× 400); (B) Western blot analysis of BACE1 expression and Tau hyperphosphorylation. *p < 0.05 vs sham-operated rats, #p < 0.05 vs AD rats. Data among multiple groups were checked by one-way ANOVA with Tukey’s post hoc test, n = 15.
Fig 2: EGCG inhibits BACE1 activity and Aβ1-42 expression in the hippocampus of AD rats. Sham-operated rats were used as controls, whereas AD rats were untreated or treated with 100 mg/kg EGCG, 250 mg/kg EGCG and 625 mg/kg EGCG. (A) Chemical structure diagram of EGCG. (B) Venn diagram of the intersection of the targets of EGCG from the SwissTarget Prediction database and AD-related genes from the CTD database. (C) Drug-target regulatory networks. (D) Expression of Aβ1-42 in rats. (E) Relative expression of BACE1 in rats detected RT-qPCR. (F) Activity of BACE1 protein in rats was measured. *p < 0.05 vs sham-operated rats, #p < 0.05 vs AD rats. Data among multiple groups were checked by one-way ANOVA with Tukey’s post hoc test, n = 15.
Supplier Page from Abcam for Human BACE-1 ELISA Kit